Dermal Papilla Exosomes

Overview

Parent Cell: Dermal Papilla Cells (derived from UCT-WJ-MSC mesenchymal lineage) | Lineage-specific hair follicle regeneration exosomes targeting androgenetic alopecia, alopecia areata, follicular miniaturization, and post-COVID hair loss

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

Mechanism of Action & Molecular Cargo

Anagen Phase Induction: VEGF, IGF-1, and KGF (FGF-7) activate Wnt/β-catenin signaling in outer root sheath cells, converting telogen-resting follicles to anagen growth phase and extending the anagen duration — directly counteracting the shortened anagen cycles of androgenetic alopecia.

Dermal Papilla Cell Proliferation: Exosomal cargo (IGF-1, PDGF, KGF) increases DP cell proliferation, volume, and gene expression of hair morphogenetic signals (BMP-4, NOGGIN, DKK1) — restoring the DP's capacity to drive hair shaft production.

Anti-Miniaturization: β-catenin and Sonic Hedgehog (Shh) pathway activation reverses follicular miniaturization by promoting DP cell expansion and restoring full-size follicle dermal papilla dimensions.

Perifollicular Angiogenesis: VEGF-driven capillary formation around hair follicle units improves nutrient delivery and oxygen tension — critical for sustaining the energy-intensive anagen growth phase.

Anti-Inflammatory Scalp Microenvironment: miRNA cargo (miR-21, miR-146a) suppresses inflammatory infiltrates around follicular units — directly relevant in alopecia areata where Th1/Th2 follicular attack drives hair loss.

Key Molecular Cargo

Therapeutic Applications

• Androgenetic Alopecia (Male & Female pattern baldness)
• Alopecia Areata — immunomodulation follicular rescue
• Telogen Effluvium — rapid cycle restart
• Post-COVID Hair Loss — follicular recovery
• Follicular Miniaturization — DP restoration and anti-DHT effects
• Scalp Inflammation — anti-inflammatory perifollicular microenvironment
• Post-transplant Enhancement — improve transplanted follicle survival and density

Clinical & Preclinical Evidence

A 2025 systematic review (PMC12433634) of exosome therapy for hair loss covering 11 clinical studies (2 RCTs, 3 retrospective, 3 prospective) confirmed substantial increases in hair density (9.5–35 hairs/cm²) and hair thickness (up to 13.01 μm) with exosome preparations derived from MSCs, including umbilical cord-derived sources. No serious adverse events were reported across all studies.^[1]

In vitro dermal papilla exosomes accelerated the onset of the anagen phase and delayed catagen phase with concomitant increased expression of β-catenin and Sonic Hedgehog — confirming the primary molecular mechanism of the Akira Hair Exosome product.^[2]

Clinical data from a 72-patient prospective cohort (Wan et al., 2023) using ADSC-derived exosomes demonstrated significant improvements in hair density, thickness, and improved follicular cycling at 6 months — with the follicular mechanism (Wnt/β-catenin, VEGF, KGF) directly paralleling Akira Hair Exosome cargo.^[3]

MSC exosomes demonstrated 3× superior hair density improvement vs PRP at 6-month follow-up in a 12-patient case series (Hassan et al., 2022), with more durable results and no adverse effects — establishing exosomes as superior to PRP for alopecia treatment.^[4]

Akira Hair Exosomes' 600 billion vesicle/3 mL concentration — the highest in the Akira portfolio — reflects dose-response data from clinical studies showing greater hair density gains at higher exosome concentrations.